All Research
PAPER GFAP-PCohort Study2021
Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer's disease
In the BioFINDER-2 cohort, plasma GFAP increased early and tracked amyloid-beta rather than tau, indicating astrocyte reactivity to amyloid.
Evidence
7/10
Moderate Evidence
Sample
—
subjects
Duration
—
study period
Journal
Brain
Nov 2021
02
Key Findings
- 01
Plasma GFAP rises early and tracks amyloid-beta rather than tau
- 02
Supports GFAP as a marker of amyloid-associated astrocyte reactivity
03
Structured Methods
- Study Design
- Cohort Study
- Sample Size
- Not reported
- Study Duration
- Not reported
- Methodology
- Not reported
- Limitations
- Not reported
04
Citations & References
Cite this paper
Unknown authors (2021). Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer's disease. Brain.
Source
Publisher
Journal
Brain
PHS
671
/ 1000
T3
Longevity Operator
Sample member
Longevity Operator
The Peak Human Score · PHS v1
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation